

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Date: 17.09.2019

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Scrip Code: 531146

Sub: Intimation under Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In accordance with Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby inform you that the Company has entered into the following Agreements:

1. Vide an agreement dated September 16, 2019, acquisition of the entire (100%) Equity Share Capital of OPAL Pharmaceuticals Pty Ltd (a company incorporated in Australia, hereinafter referred to as "OPAL") (the 'Target Company') from its existing shareholders for a consideration aggregating up to (AU) \$ 420,000. On completion of all the closing formalities, the Target Company will become a 100% Subsidiary of the Company. The details of the acquisition are enclosed hereto as **Annexure A**.
2. Subsequently, vide an agreement dated September 17, 2019, disposal/sale of 25% Equity Share Capital of OPAL held by the Company to **Baxyran Healthcare Private Limited** (the 'Buyer') for a consideration of Rs. 51, 53,400/- (Rupees Fifty One Lakh Fifty Three thousand and Four Hundred Only/-) . Therefore, post the aforesaid transfer, OPAL shall cease to be Company's wholly owned subsidiary and the Company will become holder of 75% Equity Share Capital in the said subsidiary. The details of the disposal/sale of shares are enclosed hereto as **Annexure B**.

We request to take the same on your record.

Thanking You

Yours faithfully,
For Medicamen Biotech Limited

Harish Panda
Director
DIN: 01575625



Information furnished pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015 read with SEBI circular bearing Ref. No. CIR/CFD/CMD/4/2015 dated September 9, 2015

S. No.	Particulars	Details
1.	Name of the Target Company and brief details such as size, turnover etc	OPAL Pharmaceuticals Pty Ltd OPAL pharmaceuticals incorporated in Australia have achieved a turnover of (AU) \$ 695,494 [(AU) \$ Six Lakh Ninety Five Thousand Four Hundred and Ninety Four] as on 31.07.2019.
2.	Whether the acquisition would fall within Related Party Transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired	<ul style="list-style-type: none"> • The transaction would not fall under the ambit of Related Party Transaction(s) • The promoter and promoter group doesn't have any interest in the entity being acquired
3.	Industry to which the entity being acquired belong	Pharmaceutical Industry
4.	Objects and effects of acquisition	<ul style="list-style-type: none"> • The business being acquired is same of the listed entity i.e., Pharmaceutical • The said acquisition shall provide access to the Company to enter and penetrate into Australian markets and create its presence worldwide.
5.	Brief details of any Governmental or Regulatory approvals required for the acquisition	Automatic route
6.	Indicative time period for completion of acquisition	3-4 Months
7.	Nature of consideration	Purchase consideration is by way of cash aggregating upto (AU) \$ 420,000
8.	Cost of acquisition or the price at which the shares are acquired	(AU) \$ 420,000 [equivalent to Rs 2,06,13,600 (rupees Two Crore Six Lakh Thirteen thousand and Six Hundred only/-)] as on the date of agreement)
9.	Percentage of shareholding/control acquired/number of shares acquired	100% shareholding and control of OPAL i.e., 100 Equity Shares
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	OPAL pharmaceuticals have been incorporated in Australia in the year 2018 and have achieved a turnover of (AU) \$ 695,494 [(AU) \$ Six Lakh Ninety Five Thousand Four Hundred and Ninety Four]. It has got marketing authorization of 14 pharmaceuticals products to be marketed in Australia and New Zealand. The product range has good potential and we expect a turnover of 3-5 million Au Dollars in 3 years' time.

For Medicamen Biotech Limited

Harish Pande
Director
DIN: 01575625



Information furnished pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015 read with SEBI circular bearing Ref. No. CIR/CFD/CMD/4/2015 dated September 9, 2015

S. No.	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or subsidiary of the listed entity during the last financial year	Not Applicable, as on date
2.	Date on which the agreement for sale has been entered into	September 17, 2019
3.	The expected date of completion of sale/disposal	September 17, 2019
4.	Consideration received from such sale/disposal	Rs. 51, 53,400 (Rupees Fifty One Lakh Fifty Three thousand and Four Hundred Only/-)
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. if yes, details thereof	<p>BAXYRAN HEALTH CARE PVT LTD a company incorporated in India under the Companies Act, 2013, having its Registered Office at 151A, Street No.30, Block-O, Molarbund Ext., Badarpur, New Delhi - 110044</p> <p>BAXYRAN is pharmaceutical trading house engaged in registering, marketing and selling of pharmaceutical formulations, medicinal products and derma cosmetics with a special focus on Australia and New Zealand market.</p> <p>The said buyer doesn't belong to promoter/ promoter group/group companies</p>
6.	Whether the transaction would fall within related party transactions	The transaction is not falling under related party transactions
7.	In case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable

For Medicamen Biotech Limited



Harish Pande
Director
DIN: 01575625